Effectiveness of oral metronomic Vinorelbine versus Docetaxel as second-line treatment in Non-Small Cell Lung Cancer patients in real life

被引：0
|
作者：
Nikolakopoulou, Asimina [1 ]
Tzimopoulos, Konstantinos [1 ]
Tsaroucha, Emily [1 ]
Kavvada, Katerina [1 ]
Rapti, Angeliki [1 ]
机构：
[1] Hosp Chest Dis, Pulm Dept 2, Athens, Greece
来源：
EUROPEAN RESPIRATORY JOURNAL | 2020年 / 56卷
关键词：
Lung cancer; Treatments; Lung cancer - management;
D O I：
10.1183/13993003.congress-2020.1697
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
1697
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France
    Marine, Sivignon
    Stephane, Roze
    Nicolas, Plommet
    Felizzi, Federico
    Paracha, Noman
    Benjamin, Mazaleyrat
    Perol, Maurice
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (05) : 464 - 473
  • [32] A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer
    Jones, Suzanne
    Thompson, Dana
    Barton, John
    Patton, Jeff
    Shipley, Dianna
    Greco, E. Anthony
    Spigel, David
    Infante, Jeff
    Burris, Howard A., III
    CLINICAL LUNG CANCER, 2008, 9 (03) : 154 - 159
  • [33] Single agents in the second-line treatment of non-small cell lung cancer
    Belani, CP
    SEMINARS IN ONCOLOGY, 1998, 25 (03) : 10 - 14
  • [34] Geographic variation in the second-line treatment of non-small cell lung cancer
    Edelman, MJ
    Sekine, I
    Tamura, T
    Saijo, N
    SEMINARS IN ONCOLOGY, 2006, 33 (01) : S39 - S44
  • [35] An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer
    Scagliotti, G
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (16) : 2855 - 2866
  • [36] The safety of second-line treatment options for non-small cell lung cancer
    Rossi, Antonio
    Maione, Paolo
    Santabarbara, Giuseppe
    Sacco, Paola Claudia
    Casaluce, Francesca
    Sgambato, Assunta
    Barzelloni, Maria Luisa
    Palazzolo, Giovanni
    Gridelli, Cesare
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) : 471 - 479
  • [37] Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment
    Caceres-Lavernia, Haslen H.
    Neninger-Vinageras, Elia
    Varona-Rodriguez, Leslie M.
    Olivares-Romero, Yoli A.
    Sanchez-Rojas, Irlis
    Mazorra-Herrera, Zaima
    Basanta-Bergolla, Denenke
    Duvergel-Calderin, Dayanis
    Torres-Cuevas, Boris L.
    del Castillo-Carrillo, Concepcion
    MEDICC REVIEW, 2021, 23 (3-4) : 21 - 28
  • [38] Second-line treatment options in advanced non-small cell lung cancer
    de Marinis, Filippo
    Ricciardi, Serena
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S258 - S271
  • [39] COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US
    Graham, C.
    Knox, H.
    Hess, L. M.
    Jen, M.
    Carter, Cuyun G.
    Chandrawansa, K.
    Boye, M.
    VALUE IN HEALTH, 2015, 18 (07) : A457 - A458
  • [40] Future directions in the second-line treatment of non-small cell lung cancer
    Rosell, R
    Cecere, F
    Cognetti, F
    Cuello, M
    Sanchez, JM
    Taron, M
    Reguart, N
    Jablons, D
    SEMINARS IN ONCOLOGY, 2006, 33 (01) : S45 - S51
12345